Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best biotech stocks with high potential. HC Wainwright reiterated a Buy rating on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on September 17 and set a $35 price target.
Similarly, in a report released on September 11, Jason Gerberry from Bank of America Securities also reiterated a Buy rating on Catalyst Pharmaceuticals, Inc. and set a price target of $34.00.
The analyst consensus rating on Catalyst Pharmaceuticals, Inc. is a Strong Buy, with the stock’s median price target of $20.71 implying an upside of 64.17% from current levels.
Catalyst Pharmaceuticals, Inc. is a commercial-stage, biopharmaceutical company involved in the development, in-licensing, and commercialization of novel medicines for patients with difficult-to-treat and rare diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
